Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.42 - $0.59 $5,082 - $7,139
-12,100 Reduced 84.62%
2,200 $1,000
Q2 2024

Aug 14, 2024

BUY
$0.51 - $0.85 $2,244 - $3,740
4,400 Added 44.44%
14,300 $7,000
Q1 2024

May 15, 2024

BUY
$0.7 - $5.49 $6,930 - $54,351
9,900 New
9,900 $7,000

Others Institutions Holding SPRB

About SPRUCE BIOSCIENCES, INC.


  • Ticker SPRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,560,200
  • Market Cap $11.3M
  • Description
  • Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...
More about SPRB
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.